Q1: What diseases are associated with KS?

KS is strongly associated with a variety of diseases, including corneal disorders (e.g., corneal dystrophies), genetic disorders (e.g., Morquio syndrome), cartilage-related disorders (e.g., arthritis), and neurological disorders. Abnormal synthesis or metabolism of KS can lead to corneal health problems, organ damage, cartilage degeneration, and neuronal survival, and therefore has broad implications for human health and disease development.

Q2: What is the mechanism of action of KS inhibitors?

KS inhibitors act on the synthesis or degradation pathway of KS by inhibiting the activity of key enzymes, regulating gene expression, and competitive binding to substrates, thereby affecting its level and function in the organism.

Inquiry

Keratan Sulfate Inhibitor Development Service

Inquiry

Keratan Sulfate (KS) Inhibitor Development Service at CD BioGlyco

KS is a glycosaminoglycan-like molecule present in living organisms. It is found primarily in the cornea, cartilage, bone, and some neural tissues and plays an important biological function. However, several diseases are associated with metabolic disorders or abnormal synthesis of KS. By developing KS inhibitors, it is possible to regulate its synthesis and degradation processes, thereby intervening in the development and progression of related diseases. CD BioGlyco specializes in providing diversified Glycosaminoglycan Inhibitor Development Services, including KS inhibitor development services, to meet the needs of a variety of different types of clients. The processes of our services are as follows:

First, we conduct extensive biological and biochemical studies to identify suitable targets and fully investigate the specific enzymes that synthesize or degrade KS inhibitors, the key genes that regulate their synthetic pathways, etc. Then we design the structure of the inhibitor based on research findings and client requirements.
Subsequently, a large number of compounds are screened for potential drug candidates capable of interfering with the synthesis or degradation pathways of KS by techniques such as high-throughput screening. Based on the screened active compounds, structural optimization, and pharmacodynamic evaluation are performed to improve the selectivity, activity, and pharmacokinetic properties of the compounds.
In the late stage of inhibitor development, we subject our inhibitor candidates to in vitro cellular experiments and in vivo animal experiments to assess the effects on KS levels and related biological functions to validate the efficacy and safety. Preclinical studies on the pharmacodynamics, toxicology, and pharmacokinetics of the candidate inhibitors are conducted to prepare for entry into clinical trials.

Fig.1 Classification of KS inhibitors. (CD BioGlyco)

Applications

KS inhibitors provide a valuable way for exploring new targets and strategies by intervening in the synthesis or degradation of KS, thus contributing to the potential discovery of innovative treatment options for various medical conditions.
In biological studies, the development of KS inhibitors helps to explore the mechanism of KS action in cell signaling, tissue development, and disease development, and to further understand its function in physiological and pathological processes.
In the field of bioengineering, the application of KS inhibitors may provide new ideas for tissue engineering, biomaterial design, etc., to improve the performance of related bioengineered products by modulating the content and structure of KS in the extracellular matrix.

Frequently Asked Questions

Q1: What diseases are associated with KS?
KS is strongly associated with a variety of diseases, including corneal disorders (e.g., corneal dystrophies), genetic disorders (e.g., Morquio syndrome), cartilage-related disorders (e.g., arthritis), and neurological disorders. Abnormal synthesis or metabolism of KS can lead to corneal health problems, organ damage, cartilage degeneration, and neuronal survival, and therefore has broad implications for human health and disease development.
Q2: What is the mechanism of action of KS inhibitors?
KS inhibitors act on the synthesis or degradation pathway of KS by inhibiting the activity of key enzymes, regulating gene expression, and competitive binding to substrates, thereby affecting its level and function in the organism.

Fig.2 The range of KS chain structures. (Funderburgh, 2022)

CD BioGlyco is equipped with a team of experienced researchers. Our commitment is to deliver high-quality KS inhibitor development services that meet and exceed the expectations of our clients. For further information regarding our services, please feel free to contact us directly.

Reference